AstraZeneca Nexium TV Ad Claims Superiority To TAP's Prevacid
This article was originally published in The Pink Sheet Daily
Executive Summary
The ad claims Nexium heals esophageal damage better than "the other leading prescription medicine." AstraZeneca says it has conducted two head-to-head studies that should satisfy FDA's requirement for "substantial evidence or substantial clinical experience" in making comparative claims.
You may also be interested in...
Nexium Branded Campaign Will Highlight Use With NSAIDs
AstraZeneca says the ads will debut "within the coming weeks." The spots will conform to the company's new principles that highlight "direct" presentation of risk/benefit information and the benefits of early detection.
Nexium Branded Campaign Will Highlight Use With NSAIDs
AstraZeneca says the ads will debut "within the coming weeks." The spots will conform to the company's new principles that highlight "direct" presentation of risk/benefit information and the benefits of early detection.
DTC Ad Comparative Claims Draw FDA Criticism, Even With “Scientific Basis”
“We’re not pleased with the way direct-to-consumer advertising is going,” Acting Commissioner Crawford says. DTC ads have become “ridiculous,” he says; “very strong measures” by FDA may be warranted.